The Stock Connect Innovative Drug ETF E Fund (159316) has attracted over 350 million in net inflows for four consecutive days.

I'm LongbridgeAI, I can summarize articles.

As of 11:14, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) rose by 1.48%. Among the top ten weighted stocks, Innovent Biologics rose 1.19%, BeiGene rose 1.04%, CSPC Pharmaceutical Group fell 1.66%, Akeso rose 5.92%, China National Pharmaceutical Group rose 2.35%, Hansoh Pharmaceutical rose 0.49%, Simcere Pharmaceutical rose 1.65%, Kelun-Biotech rose 0.88%, Zai Lab rose 2.07%, and Concert Pharmaceuticals-B fell 2.99%.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows, recording a net capital inflow of 24.9706 million yuan in the previous trading day. As of the previous trading day, the fund has seen consecutive net capital inflows for 4 days, totaling over 350 million yuan, and over 1.6 billion yuan in the past 20 days. The fund's average daily turnover in the last month was 1.504 billion yuan, ranking first among peers, with active on-exchange trading and strong liquidity.

In terms of news, the mid-year report window for the innovative drug sector is approaching. In Q1 2026, several innovative drug companies achieved high revenue growth of over 40% year-on-year, and some biotechnology companies successfully turned a profit. If the earnings realization of leading innovative drug companies continues the high-growth trend from Q1, market focus on the sector may gradually shift from "expectation repair" to "earnings verification." Zhaojian New Drug issued a profit warning update, forecasting a pre-increase in half-year attributable net profit of 885%-1377%.

Open Securities further pointed out that with the continuous recovery of global biomedical investment and financing, coupled with the sustained high prosperity of new molecular tracks such as peptides/GLP-1, ADC, and small nucleic acids, the performance of the innovative drug industry chain is continuously materializing. Many companies released their 2026 H1 earnings forecasts, showing generally outstanding performance. Benefiting from the continuous volume increase of self-developed products and the gradual landing of overseas licensing revenues, innovative drug companies have seen continuous high revenue growth and accelerated profit release.

The management fee rate for the Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee rates can effectively reduce cost expenditures for investors.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product tracking the Hang Seng Innovative Drug Index in the market, possessing high elasticity and scarcity, helping investors better seize this round of Hong Kong stock innovative drug investment opportunities.